================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
--------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
--------------------
Date of Report (Date of earliest event reported):
April 21, 2003
BOSTON SCIENTIFIC CORPORATION
-----------------------------
(Exact name of registrant as specified in charter)
DELAWARE 1-11083 04-2695240
-------- ------- ----------
(State or other (Commission (IRS employer
jurisdiction of file number) identification no.)
incorporation)
ONE BOSTON SCIENTIFIC PLACE, NATICK, MASSACHUSETTS 01760-1537
-------------------------------------------------- ----------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (508) 650-8000
================================================================================
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Press Release issued by Boston Scientific Corporation dated April
21, 2003.
ITEM 9. REGULATION FD DISCLOSURE.
On April 21, 2003, Boston Scientific Corporation (the "Company") issued
a press release announcing the Company's earnings for the quarter ended March
31, 2003. In addition to disclosing results that are determined in accordance
with Generally Accepted Accounting Principles (GAAP), the Company also discloses
pro forma or non-GAAP results of operations that exclude certain charges. The
Company reports pro forma results in order to better assess and reflect
operating performance. These results are provided as a complement to results
provided in accordance with GAAP. Management believes the pro forma measure
helps indicate underlying trends in the Company's business, and management uses
pro forma measures to establish operational goals. Earnings guidance is provided
only on a pro forma basis due to the difficulty in forecasting and quantifying
the amounts that would be required to be included in the GAAP measure. Pro forma
information should not be considered superior to or as a substitute for GAAP
measures. A copy of the release is furnished with this report as an exhibit
pursuant to "Item 12. Results of Operations and Financial Condition" of Form 8-K
in accordance with SEC Release Nos. 33-8216 and 34-47583.
The information in this Current Report on Form 8-K and the Exhibit
attached hereto shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 or the Exchange Act, regardless of
any general incorporation language in such filing.
2
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934,
as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
BOSTON SCIENTIFIC CORPORATION
Date: April 21, 2003 By: /s/ Lawrence C. Best
--------------------------------------
Lawrence C. Best
Senior Vice President - Finance and
Administration and Chief Financial
Officer
3